# Reserpine

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/reserpine
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-29
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** Rauvolfia alkaloid, Indian snakeroot extract, Serpentine alkaloid, 3,4,5-trimethoxybenzoyl methyl reserpate, Rauwolfia extract, Sarpagandha alkaloid, 18β-hydroxyreserpine derivative

## Overview

Reserpine is a naturally occurring indole alkaloid extracted from the root of Rauwolfia serpentina that depletes catecholamines and [serotonin](/ingredients/condition/mood) by irreversibly blocking VMAT2 (vesicular monoamine transporter 2), preventing storage of [neurotransmitter](/ingredients/condition/cognitive)s in presynaptic vesicles. This mechanism produces its antihypertensive and historically noted antipsychotic effects by reducing sympathetic nervous system activity.

## Health Benefits

• Historical use for hypertension management (FDA approved 1955, though specific clinical trial data not provided in research)
• Traditional application for anxiety relief (based on historical medicinal use, no clinical evidence provided)
• Limited evidence available - research dossier lacks specific clinical trial outcomes
• No quantified health benefits documented in provided research
• Further clinical research needed to establish evidence-based benefits

## Mechanism of Action

Reserpine irreversibly inhibits VMAT2 (SLC18A2), the vesicular monoamine transporter responsible for packaging dopamine, norepinephrine, epinephrine, and [serotonin](/ingredients/condition/mood) into presynaptic storage vesicles, causing these [neurotransmitter](/ingredients/condition/cognitive)s to be degraded by MAO (monoamine oxidase) in the cytoplasm. This leads to sustained depletion of catecholamines at peripheral adrenergic nerve terminals, reducing cardiac output and peripheral vascular resistance to lower [blood pressure](/ingredients/condition/heart-health). Recovery of neurotransmitter stores requires synthesis of new VMAT2 protein, making reserpine's effects prolonged and difficult to reverse acutely.

## Clinical Summary

Reserpine received FDA approval in 1955 for hypertension treatment and was one of the earliest pharmacologically validated antihypertensive agents, with its efficacy established through observational and controlled studies conducted in the 1950s and 1960s. The Veterans Administration Cooperative Study on antihypertensives included reserpine-based regimens and demonstrated meaningful [blood pressure](/ingredients/condition/heart-health) reductions in hypertensive men, though modern large-scale RCT data specifically isolating reserpine are limited. Low-dose regimens (0.1–0.25 mg/day) have shown comparable blood pressure lowering to some modern agents in older comparative trials, but reserpine has largely been replaced due to its narrow therapeutic window and side effect profile. Evidence for anxiolytic or antipsychotic applications remains historical and anecdotal, with no modern randomized controlled trials supporting these uses.

## Nutritional Profile

Reserpine is not a nutrient or food substance; it is a bioactive indole alkaloid (C33H40N2O9, MW 608.68 g/mol) isolated primarily from the root bark of Rauwolfia serpentina (Indian snakewort). It has no macronutrient value (no protein, carbohydrate, fat, or fiber content) and is not a source of vitamins or minerals. Key pharmacological/biochemical characteristics: • Active compound concentration in dried Rauwolfia serpentina root bark: approximately 0.1–1.0% total alkaloid content, of which reserpine constitutes roughly 0.01–0.05% by dry weight. • Mechanism: Irreversibly inhibits vesicular monoamine transporter 2 (VMAT2), depleting presynaptic stores of [serotonin](/ingredients/condition/mood) (5-HT), norepinephrine (NE), and dopamine (DA) in central and peripheral neurons. • Bioavailability: Oral bioavailability is approximately 50% (variable, range ~40–60%); extensively metabolized hepatically via CYP3A4-mediated hydrolysis and demethylation. Highly lipophilic (logP ~3.3), enabling CNS penetration. • Typical pharmaceutical dosing: 0.05–0.25 mg/day for hypertension (historically up to 0.5 mg/day). • Half-life: Plasma half-life approximately 33 hours, but pharmacological duration of action extends to 24–48+ hours due to irreversible VMAT2 binding (functional recovery requires synthesis of new transporter proteins, ~days to weeks). • Related bioactive alkaloids found in Rauwolfia serpentina root alongside reserpine include ajmaline (~0.2%), ajmalicine (raubasine), serpentine, and yohimbine — each with distinct pharmacological profiles. • No meaningful caloric content, dietary fiber, or micronutrient contribution. Reserpine is classified strictly as a pharmaceutical/pharmacological compound, not a nutritional agent.

## Dosage & Preparation

No clinically studied dosage ranges, forms, or standardization details are available in the current research dossier. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Reserpine carries significant risks including depression, sedation, nasal congestion, bradycardia, and gastrointestinal disturbances such as increased gastric acid secretion that can precipitate peptic ulcers; doses above 0.25 mg/day markedly increase the risk of severe depressive episodes. It is contraindicated in patients with a history of depression, active peptic ulcer disease, ulcerative colitis, or Parkinson's disease, as [dopamine](/ingredients/condition/mood) depletion can worsen parkinsonian symptoms. Reserpine interacts dangerously with MAO inhibitors (risk of hypertensive crisis or severe CNS depression), tricyclic antidepressants (reduced antihypertensive effect), and other CNS depressants including alcohol and barbiturates. Reserpine is classified FDA Pregnancy Category C, crosses the placental barrier, and can cause neonatal respiratory depression, lethargy, and feeding difficulties; it is also excreted in breast milk and is generally avoided during pregnancy and lactation.

## Scientific Research

The research dossier indicates that reserpine received FDA approval in 1955 as one of the first agents for hypertension treatment. However, no specific clinical trials, RCTs, meta-analyses, or PubMed PMIDs are provided in the available research.

## Historical & Cultural Context

Reserpine has been used medicinally from Rauvolfia serpentina roots for treating hypertension and anxiety, rooted in traditional Indian medicine. The compound gained recognition in Western medicine with FDA approval in 1955 as one of the first antihypertensive agents.

## Synergistic Combinations

Insufficient data - no synergistic compounds identified in research

## Frequently Asked Questions

### What plant does reserpine come from?

Reserpine is extracted primarily from the roots of Rauwolfia serpentina, a shrub native to South and Southeast Asia that has been used in Ayurvedic medicine for centuries under the name 'Sarpagandha.' The root contains a complex of alkaloids including reserpine, rescinnamine, and deserpidine, with reserpine being the most pharmacologically potent and well-studied.

### What is the standard reserpine dosage for blood pressure?

For hypertension, reserpine is typically prescribed at 0.1 to 0.25 mg per day orally, with 0.1 mg/day being the preferred starting dose to minimize the risk of depression and other central nervous system side effects. Doses above 0.25 mg/day are associated with a substantially higher incidence of adverse psychiatric effects and are generally avoided in modern clinical practice.

### Can reserpine cause depression?

Yes, reserpine-induced depression is a well-documented and serious adverse effect resulting directly from its depletion of brain serotonin, dopamine, and norepinephrine, the same neurotransmitters implicated in mood regulation. This side effect was historically significant because it contributed to early scientific theories linking monoamine deficiency to clinical depression, and reserpine is absolutely contraindicated in patients with any prior history of depressive illness.

### How does reserpine differ from beta-blockers for hypertension?

Reserpine lowers blood pressure by depleting norepinephrine and epinephrine from peripheral sympathetic nerve terminals via VMAT2 inhibition, whereas beta-blockers competitively antagonize beta-1 and beta-2 adrenergic receptors without affecting neurotransmitter storage. Beta-blockers have a faster onset, reversible mechanism, and a considerably better-characterized safety profile in modern populations, making them a preferred first-line choice over reserpine in contemporary hypertension guidelines.

### Is reserpine still used today?

Reserpine remains FDA-approved and is occasionally used in combination antihypertensive products, particularly in patients with resistant hypertension who cannot tolerate or afford newer agents, but its use has declined dramatically since the 1970s. Some researchers have also investigated reserpine as a tool compound in neuroscience to study monoamine depletion models, and very low-dose reserpine (0.1 mg) has seen renewed interest in combination therapy for cost-sensitive hypertension management in developing countries.

### What are the common side effects of reserpine?

Reserpine commonly causes drowsiness, fatigue, and nasal congestion due to its mechanism of depleting neurotransmitters. Other reported side effects include gastrointestinal disturbances, sexual dysfunction, and in some cases, mood changes or lethargy. These side effects contributed to its decline in use compared to newer antihypertensive medications.

### Does reserpine interact with antidepressants or psychiatric medications?

Reserpine can have significant interactions with antidepressants, particularly SSRIs and tricyclic antidepressants, as it depletes serotonin and norepinephrine stores. Combining reserpine with monoamine oxidase (MAO) inhibitors or other psychiatric medications may increase the risk of adverse effects and is generally contraindicated. Medical supervision is essential when considering reserpine alongside any mental health medications.

### Why has reserpine use declined since its FDA approval in the 1950s?

Although reserpine was FDA-approved for hypertension in 1955, its use declined due to the emergence of newer antihypertensive drugs with more favorable side effect profiles and fewer drug interactions. The high incidence of depression, sexual dysfunction, and other adverse effects made it less desirable than alternative blood pressure medications developed in subsequent decades. Today, reserpine is rarely prescribed in modern clinical practice.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*